ClinicalTrials.gg
RecruitingNCT07668804Updated Jun 25, 2026

A Study to Evaluate the Safety and Effect of TO-O-1007 Intravitreal Implant in Subjects With Geographic Atrophy

A Phase 1/2 interventional study of TO-O-1007 (low-dose) and TO-O-1007 (high-dose) in Geographic Atrophy Due to Age-Related Macular Degeneration, sponsored by Theratocular Biotek Co.. Recruiting at 3 sites in Australia. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Theratocular Biotek Co. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Geographic Atrophy with a site in Australia — 12 open to participants now, 15 under way, 4 of them phase 3. Geographic Atrophy · Australia.

Planned enrollment
32nd of 34
31 · median 280
Started
2026
with 3 others
Phase 1/2
4 of 41
3 open now
Primary completion
2027-08
later than 4 of 14 live
Registered
41st of 41
by date

Among the 41 studies in Geographic Atrophy with a site in Australia, this one is the 32nd largest by planned enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2026, is one of 4 in phase 1/2, reaches primary completion later than 4 of the 14 other live ones, and was the 41st registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

12 of the 41 studies in Geographic Atrophy with a site in Australia are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 41 Geographic Atrophy studies recruiting now, 32 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Geographic Atrophy with a site in Australia, or all of them as a file.
02

Study summary

This study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of TO-O-1007, a biodegradable sustained-release intravitreal implant, for the treatment of Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD). A long-acting intravitreal implant providing sustained delivery of API over 6 months may slow the progression of GA lesions while reducing treatment burden associated with frequent intravitreal injections. TO-O-1007 may offer a convenient treatment option with the potential to preserve retinal structure and visual function while maintaining an acceptable safety profile.

Read the detailed description

TO-O-1007 is a biodegradable sustained-release intravitreal implant, that is injected into the vitreous cavity of the eye. The implant is designed to gradually degrade over time, providing sustained ocular delivery of API for up to 6 months following a single administration. By continuously inhibiting C3/C5 activation, TO-O-1007 is intended to slow the progression of Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD), with the goal of preserving retinal structure and visual function. In this study, TO-O-1007 will be evaluated for its safety, tolerability, pharmacokinetics, and preliminary efficacy to determine whether it may offer a durable treatment option that reduces treatment burden compared with currently available therapies requiring more frequent intravitreal injections.

03

Conditions studied

  • Geographic Atrophy Due to Age-Related Macular Degeneration

Browse trials for

Keywords

  • Geographic Atrophy
  • TO-O-1007
  • Intravitreal Implant
  • TO-I-1007
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults ≥50 years, able to provide and comply with study procedures.
  2. Non-foveal GA secondary to dry AMD, confirmed by the central reading center.
  3. Total GA area 2.5-17.5 mm² by FAF (≥1.25 mm² for at least one lesion if multifocal).
  4. BCVA ≥24 ETDRS letters (\~20/320 Snellen) in the study eye.
  5. IOP ≤21 mmHg in the study eye.

Exclusion criteria

Exclusion Criteria:

  1. Recent participation in intravitreal, GA, or treatment studies.
  2. Pregnant or nursing women.
  3. High myopia (>8 D or axial length >27 mm).
  4. Prior AMD treatment or active/secondary CNV in the study eye.
  5. Current/prior uveitis.
  6. Recent anti-complement therapy.
  7. Use of prohibited medications, investigational products, or therapies.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
31 participants (estimated)

Study arms

  • Experimental
    TO-O-1007 Low-Dose Cohort (phase I)

    3 participants will receive TO-O-1007 (low-dose)

    Drug: TO-O-1007 (low-dose)

  • Experimental
    TO-O-1007 High-Dose Cohort (phase I)

    3 participants will receive TO-O-1007 (high-dose)

    Drug: TO-O-1007 (high-dose)

  • Experimental
    TO-O-1007 Low-Dose Arm 1 (phase IIa)

    10 participants will receive TO-O-1007 (low-dose)

    Drug: TO-O-1007 (low-dose)

  • Experimental
    TO-O-1007 High-Dose Arm 2 (phase IIa)

    10 participants will receive TO-O-1007 (high-dose)

    Drug: TO-O-1007 (high-dose)

  • Sham comparator
    TO-O-1007 Sham Arm 3 (phase IIa)

    5 participants will receive a sham injection.

    Procedure: Sham injection

Interventions

  • DrugTO-O-1007 (low-dose)

    TO-O-1007 (low-dose): Participants will receive one TO-O-1007 implant administered by intravitreal injection into the study eye.

  • DrugTO-O-1007 (high-dose)

    TO-O-1007 (high-dose): Participants will receive two TO-O-1007 implants administered by intravitreal injection into the study eye.

  • ProcedureSham injection

    Sham injection: No injection is given. It is a sham injection to keep the participant masked.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAEs)

    Number and percentage of participants experiencing at least one treatment-emergent adverse event, including serious adverse events and adverse events of special interest.

    Time frame: Up to 6 months treatment duration

Secondary outcomes

  1. Geographic Atrophy Lesion Growth

    Change in the growth rate of square root-transformed total Geographic Atrophy lesion area in the study eye, assessed by fundus autofluorescence (FAF) imaging through Week 24.

    Time frame: Baseline, Week 12, and Week 24.

  2. Visual Function Assessments

    Mean change from baseline in BCVA, LL-BCVA, and low-luminance deficit (LLD), assessed using ETDRS charts under photopic and low-luminance conditions through Week 24.

    Time frame: Week 12 and Week 24.

  3. Exposure endpoint (only for phase I)

    Plasma concentrations of TO-O-1007

    Time frame: Day 1 pre-dose, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 28 post first dosing.

07

Study locations

3 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Aug 2027, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jun 25, 2026
StartActual
Jun 2, 2026
Primary completionEst.
Aug 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07668804
Lead sponsor
Theratocular Biotek Co.
Responsible party
Sponsor
First posted
Jun 25, 2026
Start date
Jun 2, 2026
Primary completion
Aug 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jun 25, 2026

Study contacts

Weian Chien
Contact
weian@metagone.com.tw
+886 (2) 2790-6566
Chung-Hsin Tsai
Contact
brian@metagone.com.tw
+886 (2) 2790-6566
Dr. Andrew Chang
principal investigator · Sydney Retina Clinic & Day Surgery

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion